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Evaluation of Dynamic Tumor-
tracking Intensity-modulated 
Radiotherapy for Locally Advanced 
Pancreatic Cancer
Akira Nakamura1, Masahiro Hiraoka1, Satoshi Itasaka2, Mitsuhiro Nakamura1, 
Mami Akimoto1, Yoshitomo Ishihara1, Nobutaka Mukumoto1, Yoko Goto1, Takahiro Kishi1, 
Michio Yoshimura1, Yukinori Matsuo1, Shinsuke Yano1 & Takashi Mizowaki1
Intensity-modulated radiotherapy (IMRT) is now regarded as an important treatment option for 
patients with locally advanced pancreatic cancer (LAPC). To reduce the underlying tumor motions and 
dosimetric errors during IMRT as well as the burden of respiratory management for patients, we started 
to apply a new treatment platform of the dynamic tumor dynamic tumor-tracking intensity-modulated 
radiotherapy (DTT-IMRT) using the gimbaled linac, which can swing IMRT toward the real-time tumor 
position under patients’ voluntary breathing. Between June 2013 and March 2015, ten patients were 
treated, and the tumor-tracking accuracy and the practical benefits were evaluated. The mean PTV 
size in DTT-IMRT was 18% smaller than a conventional ITV-based PTV. The root-mean-squared errors 
between the predicted and the detected tumor positions were 1.3, 1.2, and 1.5 mm in left-right, 
anterior-posterior, and cranio-caudal directions, respectively. The mean in-room time was 24.5 min. 
This high-accuracy of tumor-tracking with reasonable treatment time are promising and beneficial to 
patients with LAPC.
Intensity-modulated radiotherapy (IMRT) can provide an excellent dose distribution for the most complex can-
cer volumes and has the potential to drastically increase the therapeutic ratio when the target tumor is immobile. 
However, the advantages of IMRT may be impaired unless the organ motion is addressed, because underdosing 
the target or overdosing the normal tissue can occur from organ motion during beam delivery and through-
out the treatment course1. Recently, four-dimensional radiotherapy (4DRT) has been realized with technical 
innovations by adapting the treatment beam directly to the real-time moving target of thoracic and abdominal 
tumors2–7. Incorporating 4DRT into IMRT can reduce the uncertainties of IMRT for moving tumors. Various 
intractable cancers, such as pancreatic ductal adenocarcinoma, can be the target of this strategy.
Pancreatic ductal adenocarcinoma is among the most devastating malignant diseases, which is illustrated by 
its high mortality rate and its equally high incidence8. Although controversy exists in the role of conventional RT 
for unresectable locally advanced pancreatic cancer (LAPC)9, IMRT is now regarded as an important option for 
reducing doses to the adjacent organ-at-risk (OAR) and improving local control in LAPC10–13. Because respira-
tion is a major cause of pancreas movement14,15, the breath holding or respiratory gating technique during IMRT 
is recommended and widespread16. However, growing evidence suggests that these modern techniques are still 
suboptimal because of the residual motion during the breath-hold17,18 or the volatility in internal/external corre-
lation used for respiratory gating19. These uncertainties can yield a discrepancy between planned and delivered 
doses, and therefore reduce the advantage or safety of IMRT. In this context, introducing a 4DRT technique has 
the potential to refine pancreatic IMRT.
The Vero4DRT (Mitsubishi Heavy Industries Ltd, Japan and BrainLAB AG, Germany) is an innovative treat-
ment machine that has been developed since 2002 under the initiative of Kyoto University with the aim of realiz-
ing the 4D-IMRT for moving tumors. Two specific features are incorporated into the Vero4DRT for this purpose. 
First, a pair of orthogonal kV X-ray imagers on the gantry can detect the real-time 3D tumor motion. Second, 
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the gimbaled X-ray head can swing the intensity-modulated beams directly toward the moving tumor and can 
cover a field size of 15 × 15 cm, which is enough for the extent of LAPC. These features can effectively realize the 
dynamic tumor-tracking IMRT (DTT-IMRT) with real-time monitoring (Figs 1 and S1). Based on the fundamen-
tal assessments for 4DRT performance20–27, we started DTT-IMRT with Vero4DRT in June 2013, and reported 
the initial clinical outcomes26.
The objectives of this study were to report on the initial experience, the detailed analyses of tumor-tracking 
accuracy, and the practical benefits of DTT-IMRT for LAPC.
Results
Patient and treatment characteristics. From June 2013 to March 2015, a total of 10 patients were 
enrolled in this study. The patient and tumor characteristics and treatment details are summarized in Table 1. 
All patients had non-progressive and unresectable LAPC after three courses of induction chemotherapy. Visicoil 
fiducial marker (0.5 or 0.75 × 10 mm, IBA Dosimetry GmbH, Germany) insertion was performed percutane-
ously in three patients and endoscopically in seven patients with no obvious adverse events during and after the 
marker insertion. Patients were treated with 45–51 Gy in 15 fractions (a median of 48 Gy) without interruption in 
a median of 21 days. Concurrent chemotherapy included the weekly gemcitabine (1000 mg/m2) in eight patients, 
and daily S-1 (80 mg/m2, oral intake) in one patient. Gemcitabine administration was completed in six patients.




Age (years old) Mean 71
Range 64–79
PS 0/1 6/4
Tumor location Head(uncus)/Body/Tail 5/5/0
Tumor size (mm) Mean 20
Range 20–50
Clinical Stage (UICC 7th) Stage2A/2B/3 1/0/9
Treatment
Radiotherapy dose Median [Gy] 48
45/48/51 1/5/4
Induction chemotherapy Gemcitabine 9
Gemcitabine and S-1 1
Concurrent chemotherapy Gemcitabine 8
S-1 1
Maintenance chemotherapy Gemcitabine 8
Gemcitabine and S-1 1
Surgical resection 0
Table 1. Patient characteristics. Abbreviations: PS = performance status; UICC = The International Union 
Against Cancer; S-1 = a combined drug of tegafur, gimestat, and otastat potassium.
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Planning target volume size reduction and 4D dose distribution. The planning target volume (PTV) 
in DTT-IMRT was 18% smaller than that created with a conventional internal target volume (ITV) method. The 
mean of PTV in ITV method was 228 mL (range, 173–327 mL), while that in DTT-IMRT was 186 mL (range, 
144–284 mL). There was no significant difference of PTV reduction between patients with head and body tumors 
(17% and 19% in head and body tumor, respectively). All IMRT plans adopted a 5-mm CTV-to-PTV margin 
because the patient-specific modelling errors estimated after the CT simulation were less than a 5-mm. All IMRT 
plans fulfilled the dose-volume constraints on the mid-ventilation CT. The difference of dose distribution on each 
phase of 4D-CT from the planned dose on the mid-phase CT was calculated, and the planned dose distribution 
was revealed to be well reproduced on 4D-CT. Mean (±SD) difference from the planned GTV D95% and CTV 
D95% values were +1.5% (±3.4%) and +1.3% (±2.9%), respectively. Mean difference from the planned stomach 
V45 and V42 were −0.23 mL (±0.38 mL) and −1.08 mL (±1.48 mL), respectively. The doses to the stomach were 
well under the dose constraints, and 97% and 99% of the 100 4D-CT phases (10 phases × 10 pts) met the con-
straints of V45 ≤ 1 mL and V42 ≤ 5 mL, respectively. The mean difference from the planned duodenum V45 and 
V42 were −0.13 mL (±1.60 mL) and −1.29 mL (±2.01 mL), respectively. The 99% and 99% of 4D-CT phases met 
the duodenum constraints of V45 ≤ 1 mL and V42 ≤ 5 mL, respectively. The dose to the other OARs were well 
under the dose constraints. Samples of dose distribution and dose-volume histogram are shown in Figs S2 and S3.
Tumor motions. Mean ± SDs of peak-to-peak tumor motions on the simulation 4D-CT were 2.8 ± 1.8 mm, 
2.9 ± 1.3 mm, and 7.6 ± 3.8 mm in the left-right (LR), anterior-posterior (AP), and cranial-caudal (CC) direc-
tions, respectively. Those in the head tumor were 2.7 mm, 2.7 mm, and 6.8 mm, respectively, and those in the body 
tumor were 2.8 mm, 3.1 mm, and 8.4 mm, respectively.
A total of 46,320 monitoring kV-images over all patients and treatment fractions were exported from the 
Vero4DRT system and evaluated. Mean ± SDs of daily peak-to-peak tumor motions were significantly larger 
than those on simulation 4D-CT: those in LR, AP, and CC directions were 4.7 ± 2.3 mm, 6.2 ± 2.5 mm, and 
13 ± 3.3 mm, respectively. Those in the head tumor were 5.4 mm, 6.3 mm, and 13.2 mm, respectively, while those 
in the body tumor were 4.2 mm, 6.5 mm, and 13.8 mm, respectively. The tumor movement in each patient is 
illustrated in Fig. 2.
Mean ± SDs of daily maximum velocity of tumor motions were 3.0 ± 0.7 mm/s, 3.8 ± 0.4 mm/s, and 
10 ± 0.7 mm/s in LR, AP, and CC directions, respectively. Mean ± SDs of velocity in 3D radial motion was 
3.8 ± 2.9 mm/s (range, 0.0–43 mm/s).
When an average of exhale peak positions in the first/last 20 s of each treatment day were defined as the 
first/last baseline tumor positions, mean ± SDs of the end-to-end position difference in CC direction were 
−0.7 ± 1.7 mm (range, −2.8–6.5 mm). During the daily treatments, the ≥5 mm deviations of exhale peak posi-
tions from the first baseline position were observed in 0.01%, 0.3%, 1.7%, and 3.3% in LR, AP, CC, and 3D 
directions, respectively. Similarly, the ≥2.5 mm deviations of exhale peak positions were observed in 2.1%, 3.5%, 
11.1%, and 21.2% in LR, AP, CC, and 3D directions, respectively. To cover the exhale peak positional changes 
from the first baseline position, 2.6-mm, 2.8-mm, and 5.8-mm of margins in LR, AP, and CC directions, respec-
tively, were calculated according to the Van Herk formula (PTVmargin = 2.5 Σ + 0.7 σ). Even with these margins, 
however, significant positional deviations by more than the estimated margin size were observed in AP direction 
in two cases; exhale peak positions were deviated by more than AP margins in 18% and 11% of cases #1 and #5, 
respectively. Table 2 summarizes the daily motions in each patient. Samples of tumor motion are shown in Fig. S4.
Tracking error analyses. Mean ± SDs of the geometric errors between the predicted and detected marker 
were evaluated and revealed to be considerably small: 0.6 ± 1.2 mm, −0.1 ± 1.4 mm, and 0.6 ± 1.4 mm in LR, AP 
and CC directions, respectively (Table 3). The root-mean-squared errors and the 95th percentile of absolute errors 
were 1.3 and 2.7 mm, 1.2 and 2.4 mm, and 1.5 and 2.9 mm in LR, AP, and CC directions, respectively. The geomet-
ric errors of ≥5 mm were observed only for 0.09%, 0.11%, and 0.18% in LR, AP, and CC directions, respectively. 
The overall mean and the 95th percentile 3D radial errors were 2.1 and 3.9 mm, respectively.
Figure 2. Peak-to-peak tumor motion in the simulation 4D-CT and the daily treatment. Each black dot 
represents the mean amount of peak-to-peak tumor motion in the simulation 4D-CT. Each solid bar and error 
bar indicates the mean peak-to-peak tumor motion and its standard deviation during the whole treatment.
www.nature.com/scientificreports/
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Time aspects of DTT-IMRT workflow. The mean (±SD) total monitoring time (including DTT-IMRT 
delivery) per fraction was 5.8 min (±0.1 min). The mean in-room time was 24.5 min.
Clinical outcomes. With a median follow-up period of 25.9 months, the 1-year and 2-year overall survival 
(OS) from the induction chemotherapy were 100% and 50%, respectively. The median overall survival was 25.9 
months (95% confidence interval (CI) 17.4–not available). The 2-year and median progression-free survival 
(PFS) from the induction chemotherapy were 30% and 14.6 months (95% CI 7.7–not available), respectively. The 
2-year local control rate was 74%. During DTT-IMRT with gemcitabine, G3 leucopenia and G3 neutropenia were 
observed in two and one each. Two patients had G2 GI-toxicity including anorexia and nausea. At late phase, one 
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Table 2. Characteristics of daily tumor movement. *All data are shown in mean or mean (±SD) values (and 
minimum/maximum values) of daily treatment fractions. †The proportion of exhale peak tumor positions 
which deviated from the daily baseline position by more than estimated margin sizes (2.6 mm, 2.8 mm, and 
5.8 mm in LR, AP, and CC directions) is shown. Abbreviations: LR = left to right; AP = anterior to posterior; 
CC = cranial to caudal.
Pt.
Geometric error [mm] Absolute geometric error [mm]
LR AP CC LR AP CC














































































































Table 3. Geometric errors for daily treatment. All data are shown in mean or mean ± SD values (and 
minimum/maximum values) of daily treatment fractions. Abbreviations: LR = left to right; AP = anterior to 
posterior; CC = cranial to caudal.
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Discussion
The present study aimed to report on the first experiences of DTT-IMRT with the Vero4DRT to the moving target 
of LAPC under patients’ voluntary breathing. Among real-time adaptation systems2–7, the Vero4DRT system 
confers definite advantages in DTT-IMRT. First, a treatment field large enough to cover LAPC facilitates the 
accurate dose delivery within a reasonable treatment time. Second, a short interval of the monitoring imaging fre-
quency is applicable, which is necessary for the prompt detection of internal/external correlation error. Third, the 
latency with Vero4DRT is the smallest recorded (close to a 50 ms), which contributes to the overall tumor tracking 
and treatment accuracy. To recognize the benefits of this new treatment platform of DTT-IMRT, we focused on 
reporting the tumor-tracking accuracy and the practical aspects of DTT-IMRT for the treatment of LAPC.
In the current study, we estimated that the PTV size in 4DRT was reduced by 18% compared with the 
conventional ITV-based PTV. This PTV reduction itself may be beneficial to patients in terms of GI toxici-
ties. Furthermore, the benefits of our DTT-IMRT are pronounced on the accuracy and reliability in deliver-
ing intensity-modulated beams. This is because the dose-limiting GI OARs are serial organs and suffer from a 
high-dose to small volume28,29, which can theoretically appear due to the dose uncertainties in IMRT for moving 
tumor. The accuracy of our DTT-IMRT system is supported by the smallest tumor-tracking errors, in which 
the presented 95th percentile geometric errors were 2.7 mm, 2.4 mm, and 2.9 mm in LR, AP, and CC directions, 
respectively. This accuracy is as high as the robotic tracking system for upper abdominal tumor, in which Winter 
et al. reported the 95th percentile errors of 2.1 mm, 1.8 mm, and 3.3 mm in LR, AP, and CC directions, respectively, 
during stereotactic body radiotherapy (SBRT) in 27 patients with liver cancer radiotherapy30. Overall, we con-
cluded it was acceptable to use a 5-mm expansion for CTV-to-PTV margin in DTT-IMRT for LAPC. This margin 
size contributes to the reduction of PTV, and is also beneficial to patients compared with a 1–2 cm expansion 
recommended when daily image guidance is unavailable16,31.
The investigation of velocity of LAPC motion was unique in the present study (Table 2); the 3D radial motion 
of 3.8 mm/s was smaller than that in lung and liver tumors, and well within the maximum velocity of 152 mm/s in 
the gimbaled head motion at isocenter level. The averaged in-room treatment time of 24.5 min is relatively shorter 
than that in previous lung and liver SBRT studies (34.4–36 min)4,24, likely because the number of fractions is larger 
so that the daily dose (3.0–3.4 Gy) and the monitor units are smaller despite the step-and-shoot IMRT delivery.
The conventional respiratory-managed IMRT is currently an important treatment option for LAPC, but is 
subjected to underlying uncertainties; we presented the discrepancy of tumor motions between the simulation 
4D-CT and the daily treatment (Fig. 2) which agrees with previous reports31–36. Additionally, we showed that a 
variety of the intrafractional baseline drift of tumor positions appeared in all 10 patients (Table 2 and Fig. S4). The 
estimated margins with van Herk formula to compensate the baseline drift of exhale peak tumor position were 
significantly large in CC direction, but obviously insufficient in AP direction in two patients who had relatively 
larger baseline drifts among participants. This implicates a difficulty of estimating population-based margins 
for respiratory-gating, and poses some challenges to the accurate delivery of IMRT with the respiratory gating 
strategy37. Also, recent reports revealed the residual tumor motions during breath holding with 2.9 mm (superior) 
and 3.8 mm (inferior), or up to 11.0 mm in superior-inferior direction17,18. This level should be nontrivial when 
breath-hold IMRT delivers an aggressive dose with steep dose gradients or a hypofractionated dose regimen. 
The presented uncertainties in tumor positions together with these previous studies highlight the benefits of 
DTT-IMRT for LAPC. Because these uncertainties cannot be reflected on a single simulation CT/4D-CT, we did 
not focus on the dosimetric advantages of DTT-IMRT over the respiratory-managed IMRT.
One key concern in IMRT delivery for moving tumors is the possibility of interplay between tumor motion and 
multi-leaf collimator (MLC) motion. Reportedly, large dose variations can appear in a single fraction in IMRT for 
moving tumors38, and we also observed this phenomenon in the quality assurance (QA) process by a moving phantom; 
the γ index passing rates with the criterion of 3%/1 mm was 69.8% without tracking39. Although a series of previous 
Structure Constraints
PTV-boost D95% = 100%*
PTV D98% > 36 Gy†
Stomach, Duodenum V45Gy < 1.0 mL‡
V42Gy < 5.0 mL
V39Gy < 25.0 mL
POV (each) V39Gy < 30.0 mL
V36Gy < 45.0 mL
Kidney (each) V20Gy < 30%
Liver Dmean < 30 Gy
Spinal Cord Dmax < 36 Gy
Table 4. Dose-volume constraints for the IMRT plan. Abbreviations: Dxx% = the dose covering the ≥xx% 
of the structure volume; Dmax = maximum dose; Dmean = mean dose; VxxGy = the volume of the structure 
receiving >xx Gy; PTV-boost = PTV minus POV structures; POV = each planning organs-at-risk structure 
for the stomach or duodenum. *The dose relative to the prescription dose. †The whole PTV was kept over 36 Gy 
according to consensus guidelines10. ‡The V45 was determined referring to previous reports; 55 Gy/28–30 fr. 
to 1–2 mL of stomach or duodenum significantly associated with severe GI toxicities28,29 and this dose/fraction 
approximates 45 Gy/15 fr. with regards to the late effects.
www.nature.com/scientificreports/
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studies demonstrated that dosimetric errors were cancelled out through multiple fractions40–42, we support the necessity 
of considering these errors because large intra- and interfractional motion variations in LAPC are observed and it is 
obscure whether the errors are properly cancelled under such a motion. The dosimetric accuracy in a single fraction of 
our DTT-IMRT is high (the γ index passing rates, 92.9% ± 4.0%)39, which indicates that DTT-IMRT can minimize the 
dosimetric errors from the interplay and realize a reliable IMRT delivery for moving targets.
Figure 3. 4D modeling. During 4D modelling, the fluoroscopic kV images (upper left) are acquired from 
the orthogonal kV imagers on the gantry, and both ends of the linear fiducial marker inside the tumor are 
automatically detected. Simultaneously, the position and motion of the infrared (IR) marker on the patient’s 
abdomen is captured (green curve in the upper right column). The correlation model between the internal 
marker and the IR marker motion is generated, and then the marker motion and the predicted marker motion 
are depicted on the right lower columns in three directions. Finally, the mean and SDs of the differences 
between the detected marker position and the predicted position are calculated and shown in lower left column 
(modeling errors).
Figure 4. kV and MV X-ray monitoring images during DTT-IMRT. During DT-IMRT beam delivery, 
the predicted position of the internal fiducial marker (green x) and tolerance circle (a 3-mm radius) are 
superimposed on the orthogonal fluoroscopic kV images. The kV images are updated every 1 sec. When the 
predicted positions deviate from the actual fiducial marker positions, observers can consider the recalibration of 
the 4D model.
www.nature.com/scientificreports/
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The uncertainty due to internal-external correlation change is also a relevant issue in 4DRT with IR tracking 
technique25. The internal-external correlation model is vulnerable to the changes of motion patterns of internal 
tumor or external IR marker. As described above, there are a variety of the baseline drift of tumor positions, 
which is one example of introducing the changes of tumor motion patterns. In our Vero4DRT system, we adopted 
an imaging interval of every 1 second and could detect large or continuous deviations of the predicted marker 
from the tolerance circle. This real-time visualization system enhances the reliability of DTT-IMRT delivery, and 
contributed to the reduction of geometric errors.
We demonstrated the tumor tracking and dosimetric accuracy during DTT-IMRT but, however, we admit there 
are also assumptions in this study. First, we did not investigate if the implanted marker is an adequate surrogate for 
the tumor position by using a daily soft tissue imaging, such as cone beam CT (CBCT). Although Van der Horst et 
al. showed that there is no migration of fiducials with time43 and we also confirmed it with the follow-up CT images 
after DTT-IMRT (data not shown), a daily soft tissue imaging should be ideally used to assess the target and marker 
positions during treatment course. Similarly, we did not visualize the location of OARs with respect to the target 
during the treatment. We demonstrated that the dose distribution on each phase of the simulation 4DCT is well 
acceptable, but the delivered dose to luminal OARs can become obscure when their position and volume change 
greatly, as we reported previously44. Now that Vero4DRT system is equipped with 4D-CBCT function, future studies 
with 4D-CBCT prior or after daily treatment will shed light on the adequacy of the marker and target position as well 
as the interfractional dosimetric changes in OARs during DTT-IMRT treatment course.
Recently, the image-guided RT arsenal was updated to include a new real-time soft tissue imaging technique, 
such as the magnetic resonance image (MRI)-guided RT45. Although both Vero4DRT and MRI-RT systems can 
address the issues in IMRT for moving tumors, the major advantage of Vero4DRT is the aforementioned ability to 
swing intensity-modulated beam toward tumor and it does not require patients’ contribution for breath-holding 
to achieve an accurate or efficient tumor tracking. This results in the reduced in-room treatment time and the 
minimized patient burden, especially in elderly patients or those who feel uncomfortable in controlling respira-
tion. In addition, Vero4DRT does not have contraindications, including a pacemaker and non-MR compatible 
implants. The drawback of Vero4DRT is that it requires additional radiation exposure and an inserted fiducial 
marker. Further, the movement of OARs during DTT-IMRT cannot be assessed in Vero4DRT. Overall, both 
Vero4DRT and MRI-RT systems have demonstrated high accuracy in real-time tumor tracking45. These inno-
vations in 4DRT have a strong potential to improve the clinical outcomes and should be further investigated in 
clinical studies.
DTT-IMRT with Vero4DRT is applicable to cancers that satisfy two key features: the tumor should be acces-
sible to a fiducial marker, and the treatment field should be within 15 × 15 cm. As presented in the current study, 
our first target was LAPC. Although the evaluation of clinical outcomes was beyond the scope of this study, we 
observed a promising local control rate (the 2-y local control rate of 74%) with a median survival of 25.9 months 
at a median follow-up period of 25.9 months. These promising outcomes inspired our inclination to further use 
the advantage of DTT-IMRT, and we started an early phase II multi-institutional study in 2015 to test the feasibil-
ity of DTT-IMRT for LAPC (UMIN000017521).
In summary, the clinical application of DTT-IMRT for LAPC patients was investigated. The 18% reduction 
of PTV with DTT-IMRT was observed compared with the conventional ITV-based approach. The dose distri-
bution on a representative CT is recalculated on each of 4D-CT phase to confirm the target coverage and OAR 
dose sparing during DTT-IMRT. The QA process confirmed that DTT-IMRT minimized the dosimetric errors 
from the interplay between tumor motion and MLC motion. The detailed analyses on daily tumor motions and 
tumor-tracking errors revealed that the 95th percentiles of tumor-tracking errors were 2.4–2.9 mm despite a vari-
ety of the intrafractional and interfractional tumor motions in all 10 patients. The in-room treatment time was 
24.5 min on average. The preliminary results on local tumor control and toxicity were promising, and an early 
phase II multi-institutional study was established to investigate the feasibility of DTT-IMRT for LAPC.
Methods
Patients eligibility criteria. This was a single-institution study, approved by the Institutional Review Board 
(Ethics Committee Graduate School and Faculty of Medicine Kyoto University, KUHP-E1675) in compliance 
with the Helsinki Declaration. The primary endpoint of this study was to evaluate the accuracy of DTT-IMRT 
for abdominal cancer, and the eligibility criteria included patients with clinical stage II–III of unresectable LAPC 
who received neither curative-intent surgery nor radiotherapy, had pathological confirmation of adenocarci-
noma, and provided written informed consent.
CT simulation. One Visicoil was implanted inside the tumor. At least 1 week after the insertion, patients 
were immobilized in the BodyFix system (Medical Intelligence, Germany) with both arms raised overhead. After 
≥3 hours of fasting time, patients were examined with contrast-enhanced computed tomography (CT) under 
free breathing using a LightSpeed RT 16-slice CT simulator (GE Healthcare, UK) and a real-time positioning 
management system (Varian Medical Systems, USA). The periodic whole images were sorted into 10 phased 
bins of 4D-CT images using the Advantage Workstation (GE Healthcare, UK). Following the CT simulation, 4D 
modeling was performed on Vero4DRT to assess the patient-specific modelling error.
Treatment planning. The gross tumor volume (GTV) included the tumor and metastatic lymph nodes. The 
clinical target volume (CTV) was defined as GTV plus a 5-mm margin as well as the retropancreatic space and 
the paraaortic lymph nodes between the celiac axis and the superior mesenteric artery. These target volumes and 
the luminal OARs (the stomach and the duodenum) were delineated on all 10 phases of 4D-CT and were overlaid 
onto a mid-ventilation phase. The CTV-to-PTV margin was defined as the sum of a setup error (1.0 mm) and 
additional margins, which compensate the 4D modelling error (mean + 2 SD mm), baseline drift of abdominal 
www.nature.com/scientificreports/
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position, and mechanical errors (<0.5 mm)27. When the sum of these margins exceeds 5 mm, the CTV-to-PTV 
margin size was defined as 5 mm. The stomach and the duodenum were regarded as critical OARs for severe gas-
trointestinal (GI) toxicities28,29. To mitigate the interfractional dose changes, the planning organs-at-risk volume 
was created with 3- to 7-mm margin sizes at the discretion of the treating physician44,46. Other OARs, including 
the bowels, the liver, the kidneys, and the spinal cord, were also delineated on the mid-ventilation phase.
The IMRT treatment planning was performed on the iPlan RT Dose (BrainLab, Germany). Six coplanar 
or non-coplanar 6-MV photon beams (80°–280° in every 40°) were used and the anterior beams were avoided 
because the depth-dose distribution was influenced by the respiratory movement of abdominal wall. The pre-
scription dose was specified to D95 (the dose that covers 95% of the structure) of PTV-boost, a volume that 
subtracted the planning organs-at-risk from PTV. The choice of prescription dose was individualized between 45 
and 51 Gy/15 fr. by achieving the dose constraints for OARs. The whole PTV was kept over 36 Gy according to 
consensus guidelines10. The dose constraints for OARs were as follows: V20 (volume receiving ≥20 Gy) of at least 
ipsilateral kidney ≤30%; the mean dose of liver ≤30 Gy; the maximum dose to spinal cord <36 Gy; the V42 and 
V45 of the integrated luminal OARs (stomach or duodenum) ≤5 mL and ≤1 mL, respectively. The V45 was deter-
mined referring to previous reports; 55 Gy/28–30 fr. to 1–2 mL of stomach or duodenum significantly associated 
with severe GI toxicities28,29 and this dose/fraction approximates 45 Gy/15 fr. with regards to the late effects. The 
dose constraints are summarized in Table 4. The monitor units were calculated with the X-ray voxel Monte Carlo 
algorithm, with a spatial resolution of 2 mm and a variance of 2%.
4D dose calculation and Quality assurance. To assess the dose distribution on each phase of 4D-CT, the 
monitor units and leaf motion were imported from iPlan and were used to simulate step-and-shoot IMRT with 
in-house developed Monte-Carlo simulation, as described previously47. A four-axes moving phantom was used 
to assess the differences between the planned dose-distribution and the delivered doses during static and moving 
conditions. This QA system and detailed procedure were described previously39.
Dynamic tumor-tracking IMRT procedure. DTT-IMRT consists of the following four steps: (1) Patients 
are immobilized in BodyFix and the bony-based setup error correction is performed. (2) A 4D model is built 
immediately before the daily treatment. A pair of gantry-mounted orthogonal X-ray imagers and an infrared (IR) 
(ExacTrac, BrainLAB AG, Germany) marker on the upper abdomen (Fig. 1) are utilized to generate a correlation 
4D model between the internal target and external surface of the patient’s abdomen (Fig. 3). Once established, 
the correlation model allows Vero4DRT to predict the future target position based on the position and movement 
of the IR marker. (3) The gimbaled head swings the intensity-modulated beams to follow the target trajectory in 
real-time under free breathing using the 4D model and IR marker. During DTT-IMRT, the Visicoil is monitored 
every 1 second with kV and MV X-ray imagers. The predicted marker positions are superimposed on the kV 
images and are surrounded by a 3-mm radius of tolerance circle (Fig. 4). (4) The 4D model is rebuilt when the 
operator observes that the marker has deviated from the predicted position and is systematically outside of the 
tolerance circle.
Evaluation. The following factors were evaluated. (1) The volume reduction of PTV between DTT-IMRT and 
the conventional ITV method, which creates PTV by adding a 5-mm margin to the sum of CTVs on all 4D-CT, 
was evaluated. (2) The dose distribution on each phase of 4D-CT was evaluated. (3) The differences between the 
tumor movement on the simulation 4D-CT and that on daily treatments were studied. The peak-to-peak, velocity, 
and the baseline exhale tumor positions were analyzed. Additionally, the margin sizes to compensate the change 
of baseline exhale peak positions were estimated according to the Van Herk formula. (4) The geometric errors 
between the predicted and the detected positions were evaluated. (5) The in-room time for the daily treatment 
was measured. Clinical outcomes were also evaluated, including OS, PFS, and the toxicity. The survival outcomes 
were calculated from day 1 of the induction chemotherapy and were estimated by Kaplan-Meier method. Toxicity 
was graded according to the NCI Common Terminology Criteria for Adverse Events, version 4.0.
Ethics approval and consent to participate. This study was approved by the Institutional Review Board 
in Kyoto University Hospital. (reference number: KUHP-E1675).
Availability of Data and Materials
The datasets used during the current study are available from the authors on reasonable request.
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